Etude Des Résistances Adaptatives Aux Inhibiteurs De Tyrosine Kinase De L’EGFR Dans Les Cancers Bronchiques

Total Page:16

File Type:pdf, Size:1020Kb

Etude Des Résistances Adaptatives Aux Inhibiteurs De Tyrosine Kinase De L’EGFR Dans Les Cancers Bronchiques Thèse d’exercice Faculté de Pharmacie Année 2020 Thèse N° MÉMOIRE DU DIPLÔME D'ÉTUDES SPÉCIALISÉES D’INNOVATION PHARMACEUTIQUE ET RECHERCHE TENANT LIEU DE THÈSE D’EXERCICE POUR LE DIPLÔME D’ÉTAT DE DOCTEUR ENPHARMACIE Présentée et soutenue publiquement le 24 septembre 2020 par Sarah FIGAROL Née le 19 septembre 1989 à Toulouse Etude des résistances adaptatives aux inhibiteurs de tyrosine kinase de l’EGFR dans les cancers bronchiques Thèse dirigée par Gilles Favre Examinateurs : M. Franck Saint-Marcoux, président du jury M.Gilles Favre, directeur de thèse M. Jean-Marie Canonge, juge M. Julien Mazières, juge M. Antonio Maraver, juge Thèse d’exercice Faculté de Pharmacie Année 2020 Thèse N° MÉMOIRE DU DIPLÔME D'ÉTUDES SPÉCIALISÉES D’INNOVATION PHARMACEUTIQUE ET RECHERCHE TENANT LIEU DE THÈSE D’EXERCICE POUR LE DIPLÔME D’ÉTAT DE DOCTEUR ENPHARMACIE Présentée et soutenue publiquement le 24 septembre 2020 par Sarah FIGAROL Née le 19 septembre 1989 à Toulouse Etude des résistances adaptatives aux inhibiteurs de tyrosine kinase de l’EGFR dans les cancers bronchiques Thèse dirigée par Gilles Favre Examinateurs : M. Franck Saint-Marcoux, président du jury M.Gilles Favre, directeur de thèse M. Jean-Marie Canonge, juge M. Julien Mazières, juge M. Antonio Maraver, juge Sarah FIGAROL | Thèse d’exercice | Université de Limoges |2020 3 Licence CC BY-NC-ND 3.0 Liste des enseignants Le 1er septembre 2019 PROFESSEURS : BATTU Serge CHIMIE ANALYTIQUE CARDOT Philippe CHIMIE ANALYTIQUE ET BROMATOLOGIE DESMOULIERE Alexis PHYSIOLOGIE DUROUX Jean-Luc BIOPHYSIQUE, BIOMATHEMATIQUES ET INFORMATIQUE FAGNERE Catherine CHIMIE THERAPEUTIQUE - CHIMIE ORGANIQUE LIAGRE Bertrand BIOCHIMIE ET BIOLOGIE MOLECULAIRE MAMBU Lengo PHARMACOGNOSIE ROUSSEAU Annick BIOSTATISTIQUE TROUILLAS Patrick CHIMIE PHYSIQUE - PHYSIQUE VIANA Marylène PHARMACOTECHNIE PROFESSEURS DES UNIVERSITES - PRATICIENS HOSPITALIERS DES DISCIPLINES PHARMACEUTIQUES : PICARD Nicolas PHARMACOLOGIE ROGEZ Sylvie BACTERIOLOGIE ET VIROLOGIE SAINT-MARCOUX Franck TOXICOLOGIE ASSISTANT HOSPITALIER UNIVERSITAIRE DES DISCIPLINES PHARMACEUTIQUES : CHAUZEIX Jasmine HÉMATOLOGIE JOST Jérémy PHARMACIE CLINIQUE MAITRES DE CONFERENCES : BASLY Jean-Philippe CHIMIE ANALYTIQUE ET BROMATOLOGIE BEAUBRUN-GIRY Karine PHARMACOTECHNIE BÉGAUD Gaëlle CHIMIE ANALYTIQUE ET CONTRÔLE DU MÉDICAMENT Sarah FIGAROL | Thèse d’exercice | Université de Limoges |2020 4 Licence CC BY-NC-ND 3.0 BILLET Fabrice PHYSIOLOGIE CALLISTE Claude BIOPHYSIQUE, BIOMATHEMATIQUES ET INFORMATIQUE CHEMIN Guillaume BIOCHIMIE CLÉDAT Dominique CHIMIE ANALYTIQUE ET BROMATOLOGIE COMBY Francis CHIMIE ORGANIQUE ET THERAPEUTIQUE COURTIOUX Bertrand PHARMACOLOGIE, PARASITOLOGIE DELEBASSÉE Sylvie MICROBIOLOGIE-PARASITOLOGIE- IMMUNOLOGIE DEMIOT Claire-Elise PHARMACOLOGIE FABRE Gabin SCIENCES PHYSICO-CHIMIQUES ET INGÉNIERIE APPLIQUÉE FROISSARD Didier BOTANIQUE ET CRYPTOGAMIE JAMBUT Anne-Catherine CHIMIE ORGANIQUE ET THERAPEUTIQUE LABROUSSE Pascal BOTANIQUE ET CRYPTOGAMIE LAVERDET Betty PHARMACIE GALÉNIQUE LEGER David BIOCHIMIE ET BIOLOGIE MOLÉCULAIRE MARRE-FOURNIER Françoise BIOCHIMIE ET BIOLOGIE MOLÉCULAIRE MERCIER Aurélien PARASITOLOGIE MILLOT Marion PHARMACOGNOSIE MOREAU Jeanne MICROBIOLOGIE-PARASITOLOGIE- IMMUNOLOGIE PASCAUD-MATHIEU Patricia PHARMACIE GALENIQUE – BIOMATÉRIAUX CERAMIQUES POUGET Christelle CHIMIE ORGANIQUE ET THÉRAPEUTIQUE VIGNOLES Philippe BIOPHYSIQUE, BIOMATHÉMATIQUES ET INFORMATIQUE Sarah FIGAROL | Thèse d’exercice | Université de Limoges |2020 5 Licence CC BY-NC-ND 3.0 ATTACHE TEMPORAIRE D’ENSEIGNEMENT ET DE RECHERCHE : BOUDOT Clotilde MICROBIOLOGIE (du 01/09/2018 au 31/08/2020) MARCHAND Guillaume CHIMIE ORGANIQUE ET THÉRAPEUTIQUE (du 01/09/2019 au 31/08/2020) PROFESSEURS EMERITES : DREYFUSS Gilles (jusqu’au 31/03/2020) Sarah FIGAROL | Thèse d’exercice | Université de Limoges |2020 6 Licence CC BY-NC-ND 3.0 Remerciements Aux membres de mon jury. Je tiens à adresser mes remerciements au Pr Franck Saint-Marcoux pour avoir accepté de présider ma thèse ainsi qu’au Pr Jean-Marie Canonge, au Pr Julien Mazières et au Dr Antonio Maraver pour avoir accepté d’évaluer mon travail de thèse. À mon directeur de thèse. Merci au Pr Gilles Favre de m’avoir accueillie dans son équipe, de m’avoir donné les moyens de faire avancer mon projet de thèse dans des conditions idéales et d’avoir toujours su porter un regard d’ensemble sur le projet de thèse et les orientations à lui donner. À Olivier et Anne. Je remercie énormément le Dr Olivier Calvayrac, mon parrain de la Science, pour m’avoir tout appris et transmis, du western blot à la rédaction d’un papier. Merci de ton implication quotidienne dans le projet et ma thèse ainsi que pour ton grand optimisme qui m’a toujours donné du courage. Merci au Dr Anne Pradines pour sa disponibilité sans faille et sa bienveillance, pour tous ses coups de pouce qui ont permis de débloquer, recentrer, faire avancer les choses, ainsi que pour la rigueur qu’elle m’a apportée. À toutes les personnes qui ont participé à ce travail. Merci Rémi, pour tout le travail que tu as fourni pour m’aider dans les manips et surtout pour les nombreuses mises au point techniques que tu as effectuées. Merci Raghda pour la grande aide que tu m’as apportée pour la qPCR, tu es indéniablement devenue une spécialiste en la matière. Merci Célia pour prendre mon relais pour la suite des manips et pour le travail que tu es en train d’effectuer pour générer les cellules KO avec Isa que je remercie également. Je n’ai aucun doute sur le fait qu’avec vous je laisse la suite du projet entre de bonnes mains. Merci Claudine pour les ELISA. Merci Anne Casa pour ton aide pour les dd-PCR et la confection des librairies. Merci Estelle pour le marquage Beta-Gal vivo. Merci Sandra pour la génération des cellules GFP et des DTEC, ainsi que pour m’avoir aidée, remplacée dès que j’en ai eu besoin, je citerai en particulier mon épisode coronavirus-like et la fois où mon pouce avait malencontreusement trop trempé dans l’azote. Merci également aux stagiaires, Ayman et Marie, pour leur contribution au projet. Merci aux services supports et au pôle technologique du CRCT. Merci Laetitia pour l’incucyte, merci Manon pour le tri cellulaire, merci Karine et Marie pour les expérimentations de transcriptomique et leurs analyses. Merci à nos collaborateurs à Montpellier, Antonio Maraver, Jacques Colinge et leurs équipes. À tous les membres passés et présents de l’équipe 3. Merci Sandra pour ton soutien inconditionnel et pour tous les moments qu’on a partagés. Evidemment, et tu le sais, je te souhaite beaucoup de réussite pour ta thèse et pour la suite, accroche-toi et n’oublie pas de garder en tête tes objectifs et d’avoir confiance en toi et en tes capacités. Merci Rémi pour tes blagues pourries, j’ai essayé de prendre exemple mais tu es indétrônable à ce niveau. Plus sérieusement, j’ai énormément apprécié travailler avec toi et ne te souhaite que de bonnes choses pour ta vie personnelle et ta poursuite de carrière. Merci Claire pour notre point quotidien trafic SNCF/vie à la campagne, nos discussions et ta bienveillance envers moi. Sarah FIGAROL | Thèse d’exercice | Université de Limoges |2020 7 Licence CC BY-NC-ND 3.0 Merci Claudine, maman du labo et petite-routarde de la Crète, pour ta bonne humeur, c’est très agréable de travailler à tes côtés. Merci Isa de m’avoir donné le goût de l’enseignement, tu es une super prof et la pédagogie que tu emploies avec tes étudiants est exemplaire. Merci Faten, Laetitia, Magda et Simona pour m’avoir montré le chemin du doctorat, vous avez toutes été des exemples pour moi. Sébastian et Mathéa, tout comme Sandra, je vous souhaite beaucoup de réussite pour votre thèse. Merci à tous les autres membres de l’équipe, Patrick, Olivier S., Stéphanie, Aurélien, Delphine, Célia, Nésibé, Raghda, Agnese et Anaïs, ainsi qu’aux stagiaires, passés et présents. Les discussions scientifiques et extra-scientifiques que nous avons pu avoir m’ont fait grandir et ont rendu ma vie au labo très agréable. J’ai adoré ces années passées au labo avec vous, je sais bien qu’il faut partir vers d’autres horizons, couper le cordon, mais vous allez me manquer. Je souhaite le meilleur au niveau professionnel et personnel à chacun d’entre vous. À mes amis du lycée et de la fac. Merci cousine Laure pour avoir toujours été à mes côtés, m’avoir toujours conseillée et me connaître mieux que quiconque. Merci mes potes du lycée, Laure, Julien, Joël, Finette, Théo, Romain, Paul et les autres, pour m’avoir forgé un caractère de « teigne », je pense que ça m’a bien aidée dans la réalisation de cette thèse. Je suis heureuse et chanceuse de continuer à vous voir régulièrement et d’être témoin de nos progressions respectives dans la vie depuis qu’on se connait. Merci mes copines de la fac, Julie, Mayka, Camille et aussi Emilie pour m’avoir accompagnée durant les années pharma et tous les moments qu’on a passés ensemble. On peut dire qu’enfin, et ce n’est pas trop tôt, avec cette thèse, je conclue nos années pharma. Je suis ravie de continuer à vous voir souvent et qu’on continue à partager des choses. À ma famille. Je remercie grandement mes parents pour m’avoir tout donné, pour m’avoir toujours soutenue et pour m’avoir transmis la valeur du travail. Je remercie également mes frères et ma sœur, pour leur présence bienveillante dans ma vie et pour m’avoir supporté en tant que petite dernière. Je vous dis un grand merci et suis consciente de la chance que j’ai de vous avoir dans ma vie. J’adresse une pensée toute particulière à mes grands-parents, je leur dis que j’aurais aimé leur raconter tout ça et les remercie pour l’exemple qu’ils m’ont donné. Je remercie également mes belles-familles. Merci Claudie et Jérôme, Bertrand et Angéline, Thibault et Anaïs, pour l’intérêt et le soutien que vous nous manifestez, à Clément et moi.
Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • The Role of Biological Therapy in Metastatic Colorectal Cancer After First-Line Treatment: a Meta-Analysis of Randomised Trials
    REVIEW British Journal of Cancer (2014) 111, 1122–1131 | doi: 10.1038/bjc.2014.404 Keywords: colorectal; biological; meta-analysis The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials E Segelov1, D Chan*,2, J Shapiro3, T J Price4, C S Karapetis5, N C Tebbutt6 and N Pavlakis2 1St Vincent’s Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; 2Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia; 3Monash University and Cabrini Hospital, Melbourne, VIC 3800, Australia; 4The Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA 5011, Australia; 5Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA, 5042, Australia and 6Austin Health, VIC 3084, Australia Purpose: Biologic agents have achieved variable results in relapsed metastatic colorectal cancer (mCRC). Systematic meta-analysis was undertaken to determine the efficacy of biological therapy. Methods: Major databases were searched for randomised studies of mCRC after first-line treatment comparing (1) standard treatment plus biologic agent with standard treatment or (2) standard treatment with biologic agent with the same treatment with different biologic agent(s). Data were extracted on study design, participants, interventions and outcomes. Study quality was assessed using the MERGE criteria. Comparable data were pooled for meta-analysis. Results: Twenty eligible studies with 8225 patients were identified. The use of any biologic therapy improved overall survival with hazard ratio (HR) 0.87 (95% confidence interval (CI) 0.82–0.91, Po0.00001), progression-free survival (PFS) with HR 0.71 (95% CI 0.67–0.74, Po0.0001) and overall response rate (ORR) with odds ratio (OR) 2.38 (95% CI 2.03–2.78, Po0.00001).
    [Show full text]
  • IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy
    61 1 Journal of Molecular C Mancarella and Targeting IGF system in sarcoma 61:1 T45–T60 Endocrinology K Scotlandi THEMATIC REVIEW 40 YEARS OF IGF1 IGF system in sarcomas: a crucial pathway with many unknowns to exploit for therapy Caterina Mancarella and Katia Scotlandi Experimental Oncology Lab, CRS Development of Biomolecular Therapies, Orthopaedic Rizzoli Institute, Bologna, Italy Correspondence should be addressed to K Scotlandi: [email protected] This paper forms part of a special section on 40 Years of IGF1. The guest editors for this section were Derek LeRoith and Emily Gallagher. Abstract The insulin-like growth factor (IGF) system has gained substantial interest due to its Key Words involvement in regulating cell proliferation, differentiation and survival during anoikis f sarcomas and after conventional and targeted therapies. However, results from clinical trials have f IGF system been largely disappointing, with only a few but notable exceptions, such as trials targeting f targeted therapy sarcomas, especially Ewing sarcoma. This review highlights key studies focusing on IGF f clinical trials signaling in sarcomas, specifically studies underscoring the properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. This review discusses the potential roles of IGF2 mRNA-binding proteins (IGF2BPs), discoidin domain receptors (DDRs) and metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) in regulating the IGF system. Deeper investigation of these novel regulators of the IGF system may help us to further elucidate the spatial and temporal control of the IGF Journal of Molecular axis, as understanding the control of this axis is essential for future clinical studies.
    [Show full text]
  • Therapeutic Targeting of the IGF Axis
    cells Review Therapeutic Targeting of the IGF Axis Eliot Osher and Valentine M. Macaulay * Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK * Correspondence: [email protected]; Tel.: +44-1865617337 Received: 8 July 2019; Accepted: 9 August 2019; Published: 14 August 2019 Abstract: The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and development, and when deregulated makes an important contribution to disease. Here, we review the functions mediated by ligand-induced IGF axis activation, and discuss the evidence for the involvement of IGF signaling in the pathogenesis of cancer, endocrine disorders including acromegaly, diabetes and thyroid eye disease, skin diseases such as acne and psoriasis, and the frailty that accompanies aging. We discuss the use of IGF axis inhibitors, focusing on the different approaches that have been taken to develop effective and tolerable ways to block this important signaling pathway. We outline the advantages and disadvantages of each approach, and discuss progress in evaluating these agents, including factors that contributed to the failure of many of these novel therapeutics in early phase cancer trials. Finally, we summarize grounds for cautious optimism for ongoing and future studies of IGF blockade in cancer and non-malignant disorders including thyroid eye disease and aging. Keywords: IGF; type 1 IGF receptor; IGF-1R; cancer; acromegaly; ophthalmopathy; IGF inhibitor 1. Introduction Insulin like growth factors (IGFs) are small (~7.5 kDa) ligands that play a critical role in many biological processes including proliferation and protection from apoptosis and normal somatic growth and development [1]. IGFs are members of a ligand family that includes insulin, a dipeptide comprised of A and B chains linked via two disulfide bonds, with a third disulfide linkage within the A chain.
    [Show full text]
  • Correlation Between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer
    Published OnlineFirst January 31, 2012; DOI: 10.1158/1078-0432.CCR-11-1135 Clinical Cancer Predictive Biomarkers and Personalized Medicine Research Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer Fei Huang, Li-an Xu, and Shirin Khambata-Ford Abstract Purpose: This study examined potential correlations between markers related to the insulin-like growth factor-1 receptor (IGF-1R) pathway and clinical benefit from the anti–epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in metastatic colorectal cancer (mCRC). Experimental Design: Gene expression profiles for 70 pretreatment specimens from metastatic lesions of patients with chemorefractory mCRC receiving cetuximab monotherapy were analyzed using 74 predefined Gene-Chip probesets representing 33 unique IGF-1R pathway markers to determine correlations with progression-free survival (PFS) and disease control rate. Results: Higher IGF-1R, higher GRB7, and lower INSIG2 expression were associated with longer PFS with cetuximab in univariate analyses, particularly in patients with wild-type K-Ras tumors: median, 122 versus 60 days (P ¼ 0.01), 122 versus 57 days (P ¼ 0.011), and 57 versus 156 days (P < 0.0001), favoring higher IGF- 1R, higher GRB7, and lower INSIG2 expression, respectively. Lower IGF-1 expression was associated with a PFS benefit with cetuximab, whereas lower IGFBP3 and INSR expression levels showed trends for a PFS benefit. Lower INSIG2 expression (vs. higher expression) was associated with greater PFS in the high epiregulin-expressing group (P ¼ 0.001), but not in the low-expressing cohort suggesting an effect independent from the previously reported effect of epiregulin expression.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group)
    National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research Working Group (PDAC Progress Working Group) Working Group Report March 6, 2019 The report was accepted at the March 6, 2019 CTAC Meeting ______________________________________________________________________________________________________ PDAC Progress WG Report: Accepted by the Clinical Trials and Translational Research Advisory Committee on March 6, 2019 Page 1 TABLE OF CONTENTS Page National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 3 Working Group (PDAC Progress Working Group) Report Appendix 1: Progress in Pancreatic Ductal Adenocarcinoma (PDAC) Research 16 Working Group (PDAC Progress WG) 2018 Roster Appendix 2: Funded Project Summary FY 2015 – FY 2017 • NIH PDAC Funded Projects, Initiative 1: Understanding the 18 Biological Relationship Between PDAC and Diabetes Mellitus • NIH PDAC Funded Projects, Initiative 2: Evaluating Longitudinal Screening Protocols, for Biomarkers for Earl Detection of PDAC 20 and its Precursors • NIH PDAC Funded Projects, Initiative 3: Study New Therapeutic 28 Strategies in Immunotherapy • NIH PDAC Funded Projects, Initiative 4: Developing New Treatment Approaches that Interfere with RAS Oncogene- 33 Dependent Signaling Pathways • NIH PDAC Funded Projects, No Related to the Framework t 38 Initiatives Appendix 3: PDAC Publications Supported by Grants
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • A Focus on Breast Cancer
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Ther. Author Manuscript Author manuscript; available in PMC 2017 May 01. Published in final edited form as: Pharmacol Ther. 2016 May ; 161: 79–96. doi:10.1016/j.pharmthera.2016.03.003. Emerging therapeutic targets in metastatic progression: a focus on breast cancer Zhuo Li and Yibin Kang* Department of Molecular Biology, Princeton University, Princeton, NJ, 08544, United States Abstract Metastasis is the underlying cause of death for the majority of breast cancer patients. Despite significant advances in recent years in basic research and clinical development, therapies that specifically target metastatic breast cancer remain inadequate, and represents the single greatest obstacle to reducing mortality of late-stage breast cancer. Recent efforts have leveraged genomic analysis of breast cancer and molecular dissection of tumor-stromal cross-talk to uncover a number of promising candidates for targeted treatment of metastatic breast cancer. Rational combinations of therapeutic agents targeting tumor-intrinsic properties and microenvironmental components provide a promising strategy to develop precision treatments with higher specificity and less toxicity. In this review, we discuss the emerging therapeutic targets in breast cancer metastasis, from tumor-intrinsic pathways to those that involve the host tissue components, including the immune system. Keywords Breast cancer; Metastasis; Targeted therapy; Tumor microenvironment; Immunotherapy 1. Introduction The overall 5-year survival rate for breast cancer currently stands at 90% — a dramatic improvement over the 63% survival rate in the early 1960s. When stratified by stage, the 5- year survival rates have increased to 99% for localized disease and 85% for regional advanced disease, a trend that can be attributed to early diagnoses and better treatment regimens.
    [Show full text]
  • The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives
    cancers Review The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives Pierluigi Scalia 1,2,*, Antonio Giordano 1,3 and Stephen J. Williams 1,4 1 Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Biology Department, Temple University, Philadelphia, PA 19122, USA; [email protected] (A.G.); [email protected] (S.J.W.) 2 Istituto Somatogene per la Ricerca Onco-Genomica, ISOPROG, 93100 Caltanissetta, Italy 3 Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy 4 Somatolink Foundation, Inc., Philadelphia, PA 19102, USA * Correspondence: [email protected] Received: 31 December 2019; Accepted: 2 February 2020; Published: 5 February 2020 Abstract: Insulin receptor overexpression is a common event in human cancer. Its overexpression is associated with a relative increase in the expression of its isoform A (IRA), a shorter variant lacking 11 aa in the extracellular domain, conferring high affinity for the binding of IGF-II along with added intracellular signaling specificity for this ligand. Since IGF-II is secreted by the vast majority of malignant solid cancers, where it establishes autocrine stimuli, the co-expression of IGF-II and IRA in cancer provides specific advantages such as apoptosis escape, growth, and proliferation to those cancers bearing such a co-expression pattern. However, little is known about the exact role of this autocrine ligand–receptor system in sustaining cancer malignant features such as angiogenesis, invasion, and metastasis. The recent finding that the overexpression of angiogenic receptor kinase EphB4 along with VEGF-A is tightly dependent on the IGF-II/IRA autocrine system independently of IGFIR provided new perspectives for all malignant IGF2omas (those aggressive solid cancers secreting IGF-II).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]